Key-Obs SAS

Key-Obs is a preclinical Contract Research Organisation (CRO) specialized in central nervous system in vivo pharmacological studies. Key-Obs offers in vivo models and screening assays in the fields of psychiatry (schizophrenia, depression, anxiety, and addiction), cognition, neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), juvenile diseases (ADHD, autism), rare diseases (Huntington’s disease, CMT), ALS, as well as genotyping/phenotyping of various transgenic rodents.

We complete behavioural studies with histological and immunological studies to provide a multifactor analysis and optimise the information level for our clients.

Key-Obs works for major pharmaceutical and Biotech companies all over the world, as well as academic partners.

Our models are well validated, we also customize models and tests to your specific needs.

We can administrate treatments via all routes, and collect tissues samples (plasma, CSF, brain) in relation to biomarkers analysis and histological staining.
To facilitate the screening of drugs of our clients, we are also offering in vivo screening package in psychiatry at competitive price.

Publications

1. The Combination of Marketed Antagonists of α1b-Adrenergic and 5-HT2A Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence. Trovero F, David S, Bernard P, Puech A, Bizot JC, Tassin JP. PLoS One. 2016 Mar 11;11(3).
   
2. Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models. Souchet B, Guedj F, Penke-Verdier Z, Daubigney F, Duchon A, Herault Y, Bizot JC, Janel N, Créau N, Delatour B, Delabar JM. Front Behav Neurosci. 2015 Oct 20;9:267
   
3. D-amphetamine improves attention performance in adolescent Wistar, but not in SHR rats, in a two-choice visual discrimination task. Bizot JC, Cogrel N, Massé F, Chauvin V, Brault L, David S, Trovero F. Psychopharmacology (Berl). 2015 Sep;232(17):3269-86
   
4. Opposite phenotypes of muscle strength and locomotor function in mouse models of partial trisomy and monosomy 21 for the proximal Hspa13-App region. Brault V, Duchon A, Romestaing C, Sahun I, Pothion S, Karout M, Borel C, Dembele D, Bizot JC, Messaddeq N, Sharp AJ, Roussel D, Antonarakis SE, Dierssen M, Hérault Y. PLoS Genet. 2015 Mar 24;11(3)
   
5. Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships. Danysz W, Flik G, McCreary A, Tober C, Dimpfel W, Bizot JC, Kostrzewa R, Brown RW, Jatzke CC, Greco S, Jenssen AK, Parsons CG. J Neural Transm (Vienna). 2015 Sep;122(9):1221-38.
   
6. Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: implications for Down syndrome. Mouton-Liger F, Sahún I, Collin T, Lopes Pereira P, Masini D, Thomas S, Paly E, Luilier S, Même S, Jouhault Q, Bennaï S, Beloeil JC, Bizot JC, Hérault Y, Dierssen M, Créau N. Neurobiol Dis. 2014 Mar;63:92-106.
   
7. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, Fitó M, Benejam B, Langohr K, Rodriguez J, Pujadas M, Bizot JC, Cuenca A, Janel N, Catuara S, Covas MI, Blehaut H, Herault Y, Delabar JM, Dierssen M. Mol Nutr Food Res. 2014 Feb;58(2):278-88.
   
8. Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Hernández-Hernández O, Guiraud-Dogan C, Sicot G, Huguet A, Luilier S, Steidl E, Saenger S, Marciniak E, Obriot H, Chevarin C, Nicole A, Revillod L, Charizanis K, Lee KY, Suzuki Y, Kimura T, Matsuura T, Cisneros B, Swanson MS, Trovero F, Buisson B, Bizot JC, Hamon M, Humez S, Bassez G, Metzger F, Buée L, Munnich A, Sergeant N, Gourdon G, Gomes-Pereira M. Brain. 2013 Mar;136(Pt 3):957-70.
   
9. Vezatin is essential for dendritic spine morphogenesis and functional synaptic maturation. Danglot L, Freret T, Le Roux N, Narboux Nême N, Burgo A, Hyenne V, Roumier A, Contremoulins V, Dauphin F, Bizot JC, Vodjdani G, Gaspar P, Boulouard M, Poncer JC, Galli T, Simmler MC. J Neurosci. 2012 Jun 27;32(26):9007-22.
   
10. Absence of TI-VAMP/Vamp7 leads to increased anxiety in mice.
    Danglot L, Zylbersztejn K, Petkovic M, Gauberti M, Meziane H, Combe R, Champy MF, Birling MC, Pavlovic G, Bizot JC, Trovero F, Della Ragione F, Proux-Gillardeaux V, Sorg T, Vivien D, D'Esposito M, Galli T. J Neurosci. 2012 Feb 8;32(6):1962-8
    
11. Brain phenotype of transgenic mice overexpressing cystathionine β-synthase. Régnier V, Billard JM, Gupta S, Potier B, Woerner S, Paly E, Ledru A, David S, Luilier S, Bizot JC, Vacano G, Kraus JP, Patterson D, Kruger WD, Delabar JM, London J. PLoS One. 2012;7(1)
    
12. Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB. Brault V, Martin B, Costet N, Bizot JC, Hérault Y. PLoS One. 2011;6(11)
    
13. Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure. Bizot JC, David S, Trovero F. Neurosci Lett. 2011 Feb 1;489(1):20-4